Atsushi Kikuchi

Drug-coated versus conventional balloons for side branch treatment in coronary bifurcation lesions: an optical coherence tomography substudy of the OCVC-BIF randomised trial.

Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Published: May 27, 2026

Drug-coated versus conventional balloons for side branch treatment in coronary bifurcation lesions: an optical coherence tomography substudy of the OCVC-BIF randomised trial.

Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Published: May 27, 2026

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry.

Journal: International heart journal

Published: May 17, 2026

Procedural volume and outcomes of Impella support in cardiogenic shock.

Journal: Critical care (London, England)

Published: March 28, 2026

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Journal: Lancet (London, England)

Published: September 07, 2025

Clinical Phenotypes of Patients With Ischemic Cardiomyopathy After Percutaneous Coronary Intervention.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: June 29, 2025

Long-term prognosis after acute coronary syndrome due to de novo coronary artery lesions and stent thrombosis in patients on hemodialysis.

Journal: Scientific reports

Published: March 07, 2025

Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan　- Insights From the REVIEW-HF Registry.

Journal: Circulation reports

Published: February 12, 2025

Comparison of drug-coated versus conventional balloons for the side branch of the bifurcation lesion - multicenter randomized controlled study - (OCVC-BIF): Design and rationale.

Journal: Cardiovascular revascularization medicine : including molecular interventions

Published: January 26, 2025

MAGGIC risk score and drug-related adverse events of sacubitril/valsartan: Insights from the REVIEW-HF registry.

Journal: International journal of cardiology. Heart & vasculature

Published: January 05, 2025

Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry.

Journal: Journal of cardiology

Published: December 10, 2024

Comparison of Vessel Responses Following Combined Sirolimus-Eluting and Endothelial Progenitor Cell Stent and Ultra-Thin Sirolimus-Eluting Stent Implantation by Serial Optical Coherence Tomography and Coronary Angioscopy: A Multicenter Observational Study.

Journal: The American journal of cardiology

Published: November 09, 2024

Drug-coated versus conventional balloons for side branch treatment in coronary bifurcation lesions: an optical coherence tomography substudy of the OCVC-BIF randomised trial.

Drug-coated versus conventional balloons for side branch treatment in coronary bifurcation lesions: an optical coherence tomography substudy of the OCVC-BIF randomised trial.

Drug-coated versus conventional balloons for side branch treatment in coronary bifurcation lesions: an optical coherence tomography substudy of the OCVC-BIF randomised trial.

Drug-coated versus conventional balloons for side branch treatment in coronary bifurcation lesions: an optical coherence tomography substudy of the OCVC-BIF randomised trial.

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry.

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry.

Procedural volume and outcomes of Impella support in cardiogenic shock.

Procedural volume and outcomes of Impella support in cardiogenic shock.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Clinical Phenotypes of Patients With Ischemic Cardiomyopathy After Percutaneous Coronary Intervention.

Clinical Phenotypes of Patients With Ischemic Cardiomyopathy After Percutaneous Coronary Intervention.

Long-term prognosis after acute coronary syndrome due to de novo coronary artery lesions and stent thrombosis in patients on hemodialysis.

Long-term prognosis after acute coronary syndrome due to de novo coronary artery lesions and stent thrombosis in patients on hemodialysis.

Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan - Insights From the REVIEW-HF Registry.

Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan - Insights From the REVIEW-HF Registry.

Comparison of drug-coated versus conventional balloons for the side branch of the bifurcation lesion - multicenter randomized controlled study - (OCVC-BIF): Design and rationale.

Comparison of drug-coated versus conventional balloons for the side branch of the bifurcation lesion - multicenter randomized controlled study - (OCVC-BIF): Design and rationale.

MAGGIC risk score and drug-related adverse events of sacubitril/valsartan: Insights from the REVIEW-HF registry.

MAGGIC risk score and drug-related adverse events of sacubitril/valsartan: Insights from the REVIEW-HF registry.

Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry.

Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry.

Comparison of Vessel Responses Following Combined Sirolimus-Eluting and Endothelial Progenitor Cell Stent and Ultra-Thin Sirolimus-Eluting Stent Implantation by Serial Optical Coherence Tomography and Coronary Angioscopy: A Multicenter Observational Study.

Comparison of Vessel Responses Following Combined Sirolimus-Eluting and Endothelial Progenitor Cell Stent and Ultra-Thin Sirolimus-Eluting Stent Implantation by Serial Optical Coherence Tomography and Coronary Angioscopy: A Multicenter Observational Study.

Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan　- Insights From the REVIEW-HF Registry.

Prognostic Impact of Sustained Reduction of N-Terminal Pro-B-Type Natriuretic Peptide After Initiating Sacubitril/Valsartan　- Insights From the REVIEW-HF Registry.